FireCyte Therapeutics
A neuroscience-focused ophthalmology company developing multi-target fusion protein therapeutics for retinal neurodegenerative diseases. The organization combines target identification and validation in neuroinflammation with protein engineering to create intravitreally delivered biologics that modulate microglial activation and directly protect retinal neurons. Activities span target discovery, preclinical efficacy testing in ocular models, and translational collaborations with academic clinical groups.
Industries
biotechnology
health-care
medical
Products
Multi-target fusion proteins based on an endogenous CNS protein
Engineered therapeutic proteins designed to simultaneously modulate inflammatory receptors and neuronal survival receptors for retinal neuroprotection; formatted for intravitreal delivery to posterior-segment eye diseases.
Multi-target fusion proteins based on an endogenous CNS protein
Engineered therapeutic proteins designed to simultaneously modulate inflammatory receptors and neuronal survival receptors for retinal neuroprotection; formatted for intravitreal delivery to posterior-segment eye diseases.
Expertise Areas
- Ocular neurodegeneration and glaucoma
- Neuroinflammation and microglia modulation
- Protein therapeutic design and engineering
- Intravitreal drug delivery
Key Technologies
- Fusion protein engineering
- Receptor-targeted biologics (SORT1, DCC)
- iPSC-derived functional assays
- Intravitreal administration